Zanubrutinib, rituximab and lenalidomide induces deep and durable remission in TP53-mutated B-cell prolymphocytic leukemia: a case report and literature review.

Xing, Lijie; He, Qiang; Xie, Linna; Wang, Hui; Li, Zengjun

Xing, Lijie; He, Qiang; Xie, Linna; Wang, Hui; Li, Zengjun.

Afiliação

Xing L; Department of Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan.
He Q; Department of Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan.
Xie L; Department of Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan.
Wang H; Department of Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan.
Li Z; Department of Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan. zengjunli@163.com.

Haematologica ; 107(5): 1226-1228, 2022 05 01.

Article em En | MEDLINE | ID: mdl-34937321

Assuntos

Leucemia Prolinfocítica Tipo Células B; Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico; Humanos; Lenalidomida/uso terapêutico; Leucemia Prolinfocítica Tipo Células B/tratamento farmacológico; Piperidinas; Pirazóis; Pirimidinas/uso terapêutico; Rituximab/uso terapêutico; Proteína Supressora de Tumor p53/genética

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Prolinfocítica Tipo Células B Limite: Humans Idioma: En Revista: Haematologica Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google